OncoMatch/Clinical Trials/NCT04443088
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Is NCT04443088 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including INV-1120 and Pembrolizumab for cancer.
Treatment: INV-1120 · Pembrolizumab — Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer agent
Exception: LHRH agonists, bisphosphonates and denosumab allowed
Use of systemic anti-cancer agent (except luteinizing hormone-releasing hormone (LHRH) agonists, bisphosphonates and denosumab) or investigational drug ≤28 days or five half-lives whichever is shorter prior to the first dose of study treatment
Cannot have received: radiation therapy
Exception: palliative radiation therapy limited to non-target bone lesions allowed
Radiation therapy ≤28 days prior to the first dose of study treatment, or likely to require radiation therapy at any time until the 30 days after the last dose of study treatment, except for palliative radiation therapy limited to non-target bone lesions
Cannot have received: major surgery
Major surgery within 4 weeks before enrollment or surgery with ongoing post-operative complications
Cannot have received: allogeneic bone marrow or solid organ transplant
History of an allogeneic bone marrow or solid organ transplant
Lab requirements
Blood counts
Patients whose laboratory data at screening meet the acceptable criteria for bone marrow
Kidney function
Patients whose laboratory data at screening meet the acceptable criteria for renal function
Liver function
Patients whose laboratory data at screening meet the acceptable criteria for liver function
Cardiac function
Patients who have impaired cardiac function or clinically significant cardiac diseases, including congenital long QT syndrome, significant ventricular or supraventricular arrhythmias (except sinus arrhythmia or chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities), LVEF < 50% by ECHO or MUGA, or NYHA Class III-IV heart failure
Patients whose laboratory data at screening meet the acceptable criteria for bone marrow, liver function and renal function. Patients who have impaired cardiac function or clinically significant cardiac diseases, including any of the following: Congenital long QT syndrome; Significant ventricular or supraventricular arrhythmias (patients with sinus arrhythmia or chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible); LVEF < 50% by ECHO or MUGA; Other clinically significant heart disease such as known congestive heart failure New York Heart Association (NYHA) Class III-IV
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Horizon Oncology Research, LLC, · Lafayette, Indiana
- START · San Antonio, Texas
- UT Health · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify